Loading...
Loading...
Deutsche Bank reiterated its Buy rating on Team Health
TMH and raised its price target from $26 to $29.
Deutsche Bank noted, "We expect another strong quarter, driven by top-line growth that should remain balanced b/w organic (same-contract), new contract sales and contributions from M&A. In light of strong rev growth visibility, we are raising our PT to $29 (from $26) and now put the fwd EV/EBITDA at the upper end of the group's historical 8x-9x range."
Team Health closed at $26.94 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in